SCHEMBL3675561

SCHEMBL3675561

CCc1c(-c2c[c]c(C(N)=O)nc2)n(C)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 2/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 1/20 0.37
EGFR P00533 4/20 0.36
SRC P12931 1/20 0.36
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HK1 P19367 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3677515 0.83 ALDH1A1 (0.41) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL3685274 0.81 CYP11B2 (0.53) ALDH1A1HSD17B10SMN1; SMN2EGFRSRC
SCHEMBL3678477 0.72 KMT2A (0.48) ALDH1A1HPGDKDM4EMAPTMEN1
SCHEMBL10652634 0.70 ALDH1A1 (0.69) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL3683229 0.68 CYP11B2 (0.41)
SCHEMBL3675563 0.68 CYP11B2 (0.45) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL16125580 0.65 CYP11B2 (0.43) ALDH1A1HSD17B10HPGDFNTAFNTB
SCHEMBL22578240 0.64 L3MBTL1 (0.47) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL8696242 0.64 ALDH1A1 (0.66) ALDH1A1HSD17B10HPGDSMN1; SMN2KDM4E
SCHEMBL3678379 0.64 CYP11B2 (0.35) MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307371-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2017-10-04 EP disclosed
US-9242963-B2 Organic compounds NOVARTIS AG (CH) 2016-01-26 US disclosed
US-20150210672-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-07-30 US disclosed
US-20140288126-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-25 US disclosed
US-8791141-B2 Organic compounds NOVARTIS AG (CH) 2014-07-29 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261698-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 ALDH1A1 93/4885HSD17B10 280/4885HPGD 546/4885
US-20150210672-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 ALDH1A1 110/4885HSD17B10 236/4885HPGD 569/4885
US-20140288126-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 ALDH1A1 110/4885HSD17B10 236/4885HPGD 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.